跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NAT-LENALIDOMIDE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NAT-LENALIDOMIDE
Authorized
STANDARD
NAT-LENALIDOMIDE
natco pharma (canada) inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
8f0cd035e55bd439
Company
natco pharma (canada) inc
Type
Standard
Approval Details
Approval Id
8f0cd035e55bd439
Drug Approval Canada Name
NAT-LENALIDOMIDE
Product Name
NAT-LENALIDOMIDE
Status
Marketed
Status Date
2021-09-01
Original Market Date
2021-09-01
Din
02493845
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L04AX04 LENALIDOMIDE
Atc Name
l 04 ax 04
Aig Number
0152422001
Company Name
natco pharma (canada) inc
Company Address
2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario, Canada, L5N 1P7
Active Ingredients
LENALIDOMIDE
5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
8f0cd035e55bd439
Type
Standard
Back to Health Canada Approvals